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Abstract
Background: The study was to investigate whether 18F-fluorodeoxyglucose (18F-FDG) uptake, analyzed by positron
emission tomography (PET), can be used preoperatively to predict survival in Chinese patients with colorectal
carcinoma.
Methods: A prospectively maintained colorectal cancer database was retrospectively reviewed between June 2009
and December 2011. All included patients had been newly diagnosed with colorectal cancer (of various stages)
and evaluated by 18F-FDG-PET/computed tomography (CT) within the 2 weeks preceding surgery. Univariate and
multivariate analyses were used to determine whether the maximal standardized uptake value (SUVmax) and
various clinicopathological and immunohistochemical factors were correlated with survival. Receiver operating
characteristics (ROC) curve and Kaplan-Meier survival curve analyses were used to explore whether SUVmax could
predict survival in these patients.
Results: A total of 107 patients were enrolled in the study (mean age, 59.26 ± 12.66 years; 66.35 % males), with 77
surviving to the end of follow-up (average 60 months). Univariate analysis indicated that tumor size, TNM stage,
nodal metastasis, the ratio of metastasized nodes to retrieved nodes, cyclin D1 immunostaining and SUVmax
correlated with survival (P < 0.05). Multivariate analysis showed that only TNM stage and SUVmax were associated
with survival (P < 0.05). ROC curve analysis determined the optimal SUVmax cutoff for predicting survival to be 11.85
(sensitivity, 73.3 %; specificity, 75.3 %). Survival was significantly longer in patients with preoperative SUVmax ≤11.85
(P < 0.001, log-rank test).
Conclusions: SUVmax, measured by 18F-FDG-PET/CT, provides a useful preoperative prognostic factor for patients
with colorectal cancer.
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Background
Colorectal cancer is a common malignancy in the Western
world, and its incidence continues to increase in
China [1, 2]. Generally, patients are diagnosed with colo-
rectal cancer in the sixth and seventh decades of life, with
most lesions occurring in the sigmoid (30 %), rectum
(25 %) and cecum (25 %) [1]. More than 50 % of patients
with colorectal cancer will have developed metastases by
the time of diagnosis [3–6], most commonly to the liver
and lungs, highlighting the need for new markers that will
more accurately predict prognosis.
Imaging modalities are frequently used in the
screening, staging and surveillance of colorectal can-
cer. 18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography (PET) has proven particularly useful in the
clinical staging and restaging of metastases or local re-
currence of colorectal cancer [7]. However, the diagnostic
accuracy of FDG/PET is limited by nonspecific colonic
uptake of FDG that is unrelated to malignancy, as a
result of physiologic processes, inflammation or colonic
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adenomas [8]. Accumulation of FDG in a tumor is based
on enhanced glycometabolism, and there is substantial
evidence that FDG uptake in tumor cells correlates with
tumor growth rate, the potential for aggressive behavior,
and prognosis [9]. Thus, FDG-PET may be used before
surgery to assess tumor metabolism. The standardized
uptake value (SUV) is the semiquantitative parameter
most commonly used in current clinical practice to assess
the degree of FDG accumulation.
Many clinicopathological factors have been reported to
be potential prognostic markers for colorectal cancer,
including lymph node status, presence of metastases and
differentiation status [10]. In addition, the expressions of
various endogenous proteins, detectable using immuno-
histochemical (IHC) techniques, have been suggested by
some (but not all) studies to correlate with the prolifera-
tive capacity, invasive potential and/or prognosis of colo-
rectal cancer. These proteins include Ki-67, proliferating
cell nuclear antigen (PCNA), cyclin D1 (CCND1), and
nm23 (a nucleoside diphosphate kinase) [11–13].
Unfortunately, these pathological and IHC indexes can
only be assessed after surgery. Preoperative prediction of
patient prognosis would have numerous benefits, allow-
ing better selection of patients for neoadjuvant radioche-
motherapy to downstage their disease, and increasing
the feasibility of sphincter-sparing surgery. In addition,
preoperative diagnostic markers could help to evaluate
the chemosensitivity of the cancer. The present study
has investigated whether 18F-FDG uptake, analyzed by
PET, can be used preoperatively to predict survival in
Chinese patients with colorectal carcinoma. Our findings
could help to extend the use of FDG-PET/CT as a
technique for preoperative prediction of prognosis in
patients with colorectal cancer.
Methods
Patients
A prospectively maintained colorectal cancer database
was retrospectively reviewed between June 2009 and
December 2011. The patients selected for this study had
been newly diagnosed with colorectal cancer (of various
stages) and evaluated further by 18F-FDG-PET/CT within
the 2 weeks preceding surgery. Patients were excluded if
they were hyperglycemic (>9 mmol/L) on the day of the
PET/CT investigation, or had received any therapeutic or
major surgical interventions before examination. All
patients taking metformin stopped this drug for a week
before examination. Follow-up data were collected, and
each patient allocated into one of two groups (survivor or
deceased) according to their clinical outcome at an aver-
age follow-up time of 60 months. This study was approved
by the Ethics Committee of the Shanghai Cancer Center,
Fudan University, P.R. China. Written informed consent
was obtained from each patient for original data entry.
The Committee waived the need for individual consent
for subsequent studies carried out using this database.
Data collection
Clinical data: The following characteristics were ex-
tracted from the clinical records: patient gender, age, and
tumor size (cm). Tumor size was estimated by measuring
the maximal diameter of the invasive component of the
tumor.
Maximum standardized uptake value: All patients
underwent 18F-FDG PET/CT scans (Biograph, 16HR;
Siemens, Germany) during the 2 weeks immediately pre-
ceding surgery. Patients fasted for at least 4 h before the
18F-FDG PET/CT study, and blood glucose analysis of
capillary blood samples was undertaken 1 h before injec-
tion of FDG. Patients received 0.2 mCi/kg (74 MBq/kg)
of 18F-FDG intravenously, via a vein in the arm, and then
were allowed to rest until the start of the scan. With the
patient in the supine position, three-dimensional (3D)
PET acquisition was performed from the skull to the
upper thighs, with 5-7 bed positions per 2 min. The im-
ages were reconstructed with a standard algorithm pro-
vided by the manufacturer. The CT component (120 kV;
300 mA, with the electric current controlled automatically
by the CareDose4D software according to cine-oriented
image; 5-mm slice thickness, inter-slice spacing and re-
construction) was performed without intravenous contrast
or bowel preparation, for the purpose of correction of at-
tenuation and lesion localization. PET data were acquired
in the same anatomic location. The region of interest
(ROI) was delineated according to the margin of the mass
on the PET image. The FDG activity was measured by cal-
culating the maximal SUV (SUVmax) in the attenuation-
corrected PET data. The SUV was calculated using the
following formula: SUV = activity in the region of interest
(MBq/mL)/injected dose (MBq)/body weight (kg).
Pathological data: Tissue samples were processed using
a standard protocol [14]. Histological grade and type,
invasion depth and lymphovascular or nerve invasion
were determined for each patient by at least two ob-
servers, who were unaware of the results of the PET/CT
studies. The pathological results served as the reference
standard, and the tumor stage was classified according to
the seventh edition of the TNM staging system for colo-
rectal cancer. In the present study, the following patho-
logical factors were measured: TNM stage, histological
type, differentiation degree, nodal metastasis status, and
the ratio of nodal metastasis to total lymph nodes
retrieved. TNM stage was classified into 6 subgroups: Tis,
I, IIA, IIB, III and IV; histologic type was divided into 6
subgroups: adenocarcinoma, mucinous adenocarcinoma;
signet ring cell carcinoma, adenocarcinoma with a compo-
nent of mucinous adenocarcinoma, adenocarcinoma with
a component of signet ring cell carcinoma, and others;
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Table 1 Baseline patient data and univariate analysis of factors associated with survival at 60 months
Type Group Subgroup Survivor (N = 77) Deceased (N = 30) P value
Demographic data Age (years) 59.65 ± 12.75 58.27 ± 12.58 0.614
Gender Male 50 (64.9 %) 21 (70 %) 0.618*
Female 27 (35.1 %) 9 (30 %)
Pathologic factors Colorectum Colon cancer 45 (58.4 %) 15 (50 %) 0.389*
Rectal cancer 31 (40.3 %) 15 (50 %)
Tumor size (cm) 5.0 (2.0, 10.0) 3.7 (1.0, 10.0) 0.017
TNM stage Tis 2 (2.6 %) 0 <0.001*
I 15 (19.5 %) 0
IIA 21 (27.3 %) 1 (3.3 %)
IIB 10 (13.0 %) 2 (6.7 %)
III 24 (31.2 %) 14 (46.7 %)
IV 5 (6.5 %) 13 (43.3 %)
Histologic type Adenocarcinoma 67 (87.0 %) 26 (86.7 %) 0.436*
Mucinous adenocarcinoma 3 (3.9 %) 3 (10.0 %)
Signet ring cell carcinoma 1 (1.3 %) 0
Adenocarcinoma with component
of mucinous adenocarcinoma
3 (3.9 %) 1 (3.3 %)
Adenocarcinoma with component
of signet ring cell carcinoma
1 (1.3 %) 0
Other 2 (2.6 %) 0
Differentiation degree Well differentiated 4 (5.2 %) 0 0.054*
Well or moderately differentiated 4 (5.2 %) 0
Moderately differentiated 54 (70.1 %) 24 (80.0 %)
Moderately or poorly differentiated 8 (10.4 %) 3 (10.0 %)
Poorly differentiated 5 (6.5 %) 1 (3.3 %)
Undifferentiated 1 (1.3 %) 1 (3.3 %)
Nodal metastasis 0 (0,12) 2 (0,9) 0.01
Ratio of nodal metastasis
to retrieved nodes
0 % (0 %, 100 %) 8.93 % (0, 100) 0.03
Immunohistochemical factors PCNA 60 % (0 %, 95 %) 52.5 % (10, 85) 0.129
nm23 0 = "(–)" 9 (11.7 %) 5 (16.7 %) 0.65*
1 = "(±)" 11 (14.3 %) 2 (6.7 %)
2 = "(+)" 51 (66.2 %) 22 (73.3 %)
3 = "(++)" 2 (2.6 %) 0
4 = "(+++)" 4 (5.2 %) 1 (3.3 %)
Cyclin D1 0 = "(–)" 14 (18.2 %) 3 (10.0 %) 0.03*
1 = "(±)" 28 (36.4 %) 5 (16.7 %)
2 = "(+)" 31 (40.3 %0 15 (50.0 %)
3 = "(++)" 3 (3.9 %) 6 (20.0 %)
4 = "(+++)" 1 (1.3 %) 1 (3.3 %)
Ki67 50 (0,95) 45 (5,90) 0.908
Maximum standardized
uptake value
SUVmax 9.8 (4.4, 24.7) 13.6 (3.2, 34.2) <0.001
There is one missing number in “Colon or Rectal cancer” in the survivor group. And each group had a missing in “Differentiation degree”
*Means data was shown in number (percentage) and analyzed by Chi-square test. And the other data are all shown in median (minimum, maximum) and analyzed
by ANOVA
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and differentiation degree was classified into 6 subgroups:
well differentiated, well or moderately differentiated, mod-
erately differentiated, moderately or poorly differentiated,
poorly differentiated, and undifferentiated.
Immunohistochemical data: Consecutive sections with
a thickness of 4 μm were cut from representative paraffin-
embedded tumor blocks. IHC staining was performed on
an automated platform (BenchMark XT, Ventana Medical
Systems, USA) according to the manufacturer’s instruc-
tions, using the following primary antibodies: anti-PCNA
(PC10, Dako, Denmark, 1:1200); anti-cyclin D1 (EP12,
Dako, 1:200); anti-nm23 (4B2, Abzoom, USA, 1:200); and
anti-Ki67 (MIB-1, Dako, 1:200). The IHC results were
assessed by a pathologist blinded to the clinical outcome
or histopathological diagnosis. PCNA, CCND1, and Ki67
immunoreactivities were restricted to the nucleus, while
nm23 immunoreactivity was found in the cytoplasm. The
Ki67 and PCNA indexes were obtained by counting, under
a microscope, 1000 tumor cells in consecutive high-power
fields in the most reactive areas, and determining (as a
percentage) the number of these cells showing distinct
nuclear staining. Scoring of CCND1 and nm23 expression
was based on the intensity of the IHC staining and the per-
centage of positively stained cancerous cells, as described
previously [15, 16]. Nuclear CCND1 immunostaining and
cytoplasmic nm23 immunostaining was considered as
positive. Scoring was as follows: 0, no staining; ±, focal,
weak staining; 1+, weak staining in < 50 % of cells; 2+,
weak staining in > 50 % of cells or strong staining in < 50 %
of cells; 3+, strong staining in > 50 % of cells.
Statistical analysis
A generalized linear model (GLM) in R [17] was applied
to test for effects of the clinical, pathological, and IHC
factors on SUVmax. In addition, for significant factors, a
multivariate regression analysis was applied in PAST
[18] to test the correlations between the significant fac-
tors and SUVmax. Receiver operating characteristics
(ROC) analysis with calculation of the Youden index was
used to determine the optimal SUVmax cutoff value for
predicting the outcome of colorectal cancer. Kaplan–
Meier survival curves were constructed to compare sur-
vival between patients with SUVmax values either side
of this cutoff, with statistical comparisons made using
the log-rank (Mantel-Cox) test. P < 0.05 was taken to
indicate a statistically significant difference.
Results
Baseline patient characteristics
A total of 107 patients were included in the analysis: 77
in the survivor group and 30 in the deceased group.
There were no significant differences between the two
groups for age or gender (Table 1).
Univariate analysis of the factors associated with
patient survival
In the univariate analysis, the pathologic factors signifi-
cantly associated with survival were tumor size, TNM
stage, nodal metastasis, and the ratio of metastasized
nodes to retrieved nodes (all P < 0.05; Table 1). In con-
trast, lesion location, histologic type, and the degree of
differentiation were not significantly associated with
survival. Of the IHC factors assessed, only CCND1 was
significantly associated with survival (P < 0.05); PCNA,
nm23, and Ki67 showed no significant association
(Table 1). SUVmax was also associated with patient sur-
vival (P < 0.05; Table 1).
Multivariate analysis of the factors associated with
patient survival
All factors showing a significant association with survival
in the univariate analyses (P < 0.05) were entered into a
multivariate analysis. The multivariate analysis revealed
that only the TNM stage and SUVmax were independ-
ently associated with survival (P < 0.05), whereas tumor
size, nodal metastasis, the ratio of metastasized nodes to
retrieved nodes, and CCND1 were not (Table 2).
Table 2 Multivariate analysis of factors associated with survival at 60 months
B S.E. Wald df Sig. Exp(B) 95 % C.I. for Exp(B)
Lower Upper
TNM stage 1.522 0.425 12.82 1 < 0.001 4.581 1.991 10.538
Tumor size −0.006 0.180 0.001 1 0.975 0.994 0.699 1.414
SUVmax 0.261 0.091 8.268 1 0.004 1.298 1.087 1.551
Nodal metastasis 0.261 0.238 1.209 1 0.272 1.299 0.815 2.070
Ratio of nodal metastasis to retrieved nodes −0.029 0.028 1.052 1 0.305 0.972 0.919 1.027
Cyclin D1 −0.293 0.423 0.480 1 0.488 0.746 0.325 1.710
Constant −9.458 2.275 17.282 1 0.000 0.000
A multivariate regression analysis was applied in PAST to test the correlations between the significant factors and SUVmax. And only TNM stage and SUVmax are
independent risk factors for prognosis of colorectal cancer
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ROC analysis of the optimal SUVmax cutoff value for
predicting survival in patients with colorectal cancer
ROC analysis (Fig. 1) and calculation of the Youden
index revealed that the optimal SUVmax cutoff value for
predicting survival in patients with colorectal cancer was
11.85 (area under the curve, 0.763; P < 0.001). The calcu-
lated sensitivity and specificity values for this cutoff were
73.3 and 75.3 %, respectively.
Figure 2 compares the Kaplan–Meier survival curves
between patients with SUVmax ≤11.85 and those with
SUVmax >11.85. Survival was significantly longer in pa-
tients with SUVmax ≤11.85 (P < 0.001). The median sur-
vival time was 37 months in patients with SUVmax >11.85,
whereas median survival was not reached (i.e. exceeded
60 months) in patients with SUVmax ≤11.85.
The correlation between IHC factors and SUVmax
Regression analysis indicated that SUVmax showed a
significant positive correlation with the CCND1 immu-
nostaining score (Fig. 3; r = 0.63; P < 0.001). However,
SUVmax showed no significant correlations with immu-
nostaining for PCNA, Ki67, or nm23 (data not shown).
Case study
A 58-year-old male with ascending colon cancer is
described as a case study, to explore the correlations
between clinicohistopathological factors and 18F-FDG
uptake of the primary tumor. Representative PET and
CT images are shown in Fig. 4. The transaxial PET
image (Fig. 4a) indicated that focal FDG uptake in the
ascending colon (i.e. SUVmax) was 12.8, while the
transaxial CT image of the same lesion (Fig. 4b) showed
that the tumor size was 6 × 8 cm. The merged PET/CT
images (Fig. 4c) showed good correspondence. A coronal
PET image of the same lesion is presented in Fig. 4d.
Discussion
The main findings of this study are that higher TNM
stage and higher SUVmax are significantly associated
with shorter survival in patients with colorectal cancer,
Fig. 3 Correlation between cyclin D1 expression and SUVmax
Fig. 2 Comparison of survival curves for patients with SUVmax≤ 11.85
and patients with SUVmax > 11.85
Fig. 1 ROC curve analysis of the optimal SUVmax cutoff for predicting
survival in patients with colorectal cancer
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and that SUVmax is a marker of prognosis in these
patients. Specifically, we determined that the optimal
SUVmax cutoff value for predicting survival was 11.85,
with values above 11.85 being associated with signifi-
cantly shorter survival. Therefore, the measurement of
SUVmax with 18F-FDG-PET/CT scanning provides a
useful preoperative prognostic factor for patients with
colorectal cancer. If the cutoff value is changed to 17,
then the sensitivity would be of 75 % (18/24) for pre-
dicting death, which might suggest that a small propor-
tion (22.4 %, 24/107) of patients would receive intensive
treatments and that most of them (75 %) would still
benefit from the treatment.
18F-FDG PET/CT imaging has been employed widely
to identify and stage various types of cancer, including
lung cancer [19], breast cancer [20], esophageal cancer
[21], sarcoma [22], and melanoma [23], and has proven
particularly useful in the detection, staging, and surveil-
lance of colorectal cancer [24–27]. Accurate preopera-
tive visualization of cancer deposits with this technique
potentially enables surgeons to perform more complete
tumor resections, improving clinical care and long-term
survival. Semi-quantitative analysis with 18F-FDG PET/
CT is gaining popularity for predicting clinical outcomes
and determining the tumor response to treatment [28, 29],
since changes in tumor metabolism may be observed prior
to changes in tumor size. Thus, a significant change in
tumor SUV potentially could be used as a measure of the
metabolic response of the tumor to therapy. Our findings
extend the potential clinical utility of SUVmax measure-
ments, suggesting that in Chinese patients with colorectal
cancer, preoperative values ≤11.85 can be used as a prog-
nostic indicator of improved survival after surgery. This
can provide additional guidance to clinicians treating pa-
tients with this cancer.
However, 18F-FDG PET/CT imaging does have some
limitations including false-negative findings that can
occur for several reasons (e.g., inflammation, small
lesion size, and diabetes). Weston et al. found that the
sensitivity, specificity, and accuracy of PET/CT at detect-
ing colon cancer or adenomas >10 mm were 72, 90 and
88 %, respectively [28]. Sarikaya et al. [30] reported that
Fig. 4 Case study of a patient with ascending colon cancer. a Transaxial PET image showing focal FDG uptake in the ascending colon, taken at the level
indicated by the line. b Transaxial CT image of the same lesion. c Image obtained by merger of the PET and CT images. d Coronal PET image of the
same lesion
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3 of 5 patients (60 %) with false-negative PET/CT
findings had mucinous adenocarcinoma diagnosed histo-
logically. Peng et al. have shown that colonoscopy is a
necessity when incidental colorectal FDG uptake is
found on 18F-FDG PET/CT imaging [31]. These authors
also reported that the SUVmax value was higher in
patients with cancer, although a high value did not
necessarily indicate the presence of malignancy.
Regional lymph node status is an important prognostic
factor that also plays a crucial role in the selection of
postoperative therapy. Preoperative nodal staging using
imaging requires an assessment of the number of perico-
lic and mesenteric nodes that contain metastatic disease.
False-negative PET findings in regional metastatic lymph
nodes are not uncommon, occurring in part due to the
intense FDG uptake by the primary tumor that obscures
immediately adjacent structures, and in part due to the
low sensitivity of PET to microscopically involved lymph
nodes. As a result, FDG PET has been found to have a
high specificity (>90 %) for regional lymph node metas-
tases from colorectal cancer, but only a low sensitivity
(<30 %) [32, 33]. Yu et al. have reported recently that an
SUVmax cutoff of 2.0 could identify malignant juxtain-
testinal lymph nodes with a sensitivity of 91.43 % and a
specificity of 87.83 % [34], highlighting the benefits of
using SUVmax with ROC curve analysis for optimizing
the diagnostic capabilities of 18F-FDG PET/CT.
It was notable that our multivariate analysis highlighted
SUVmax and TNM stage as the two variables signifi-
cantly associated with survival. Cancer stage is well
established as a prognostic factor for colorectal cancer
[35]. Although univariate analysis revealed that tumor
size is correlated with survival, multivariate analysis
found no significant influence of this factor in Chinese
patients; this is in contrast to a recent study that re-
ported tumor size to be an independent prognostic fac-
tor in Austrian patients with colon carcinoma [36].
Whether this reflects an ethnicity-related difference re-
mains to be determined.
There is some debate as to the utility of Ki-67, PCNA,
CCND1, and nm23 expressions as prognostic factors in
colorectal cancer. Several studies have suggested that the
expressions of these proteins correlate with outcome
[11–13], whereas others have provided contradictory
data [37–40]. The reasons underlying these discrepan-
cies remain unknown. The multivariate analysis in the
present study revealed that the expressions of Ki-67,
PCNA, CCND1, and nm23 did not correlate significantly
with survival, suggesting that in Chinese patients, pre-
operative IHC assessments of these markers may not be
particularly useful indicators of prognosis after surgery.
Interestingly, we did find a significant correlation be-
tween SUVmax and CCND1 expression; the underlying
reasons for this correlation merit further study.
The present study is not without limitations. First, this
was a hospital-based study; hence, our patients may not
be sufficiently representative of the general population
in China. Second, a relatively small number of patients
were included, raising the possibility of inherent selec-
tion bias. Third, our study did not include a healthy
control group for comparison. Fourth, our study was
retrospective in nature. Finally, these patients received a
wide variety of adjuvant treatments that could not be
taken into account in the analyses. Therefore, larger
case-control and prospective randomized studies are
needed to validate and extend our findings.
Conclusions
In conclusion, TNM stage and SUVmax are independent
predictors of survival in patients with colorectal cancer,
and preoperative SUVmax values ≤11.85 are associated
with better survival. FDG-PET/CT could be used as a
method of patient stratification before surgery, helping
in the selection of appropriate therapeutic strategies.
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